Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer

World Journal of Gastroenterology

Volumn 22, Issue 2, 2016, Pages 557-566

  Nosho, Katsuhiko ^a   Sukawa, Yasutaka ^a   Adachi, Yasushi ^a   Ito, Miki ^a   Mitsuhashi, Kei ^a   Kurihara, Hiroyoshi ^a   Kanno, Shinichi ^a   Yamamoto, Itaru ^a   Ishigami, Keisuke ^a   Igarashi, Hisayoshi ^a   Maruyama, Reo ^a   Imai, Kohzoh ^b   Yamamoto, Hiroyuki ^c   Shinomura, Yasuhisa ^a  

^a SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

BRAF; Colon neoplasia; CpG island methylator phenotype; Fusobacterium species; MiR 21

Indexed keywords

CD3 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 10; MACROPHAGE INFLAMMATORY PROTEIN; MICRORNA; MICRORNA 21; PROSTAGLANDIN E2; TRANSCRIPTION FACTOR FOXP3; TUMOR MARKER;

ADAPTIVE IMMUNITY; AGED; APOPTOSIS; CANCER PREVENTION; CANCER PROGNOSIS; COHORT ANALYSIS; COLORECTAL CARCINOMA; DENDRITIC CELL; FEMALE; FUSOBACTERIUM NUCLEATUM; HOST; HUMAN; IMMUNE RESPONSE; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INTESTINE; JAPANESE (PEOPLE); LYMPHOCYTE PROLIFERATION; MAJOR CLINICAL STUDY; MALE; METAGENOMICS; MICROBIOME; MICROFLORA; MICROSATELLITE INSTABILITY; NONHUMAN; PROTEIN EXPRESSION; REVIEW; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; UNITED STATES; ANIMAL; COLORECTAL TUMOR; FUSOBACTERIUM INFECTION; GENETICS; HOST PATHOGEN INTERACTION; IMMUNOLOGY; INNATE IMMUNITY; INTESTINE FLORA; LYMPHOCYTE ACTIVATION; METABOLISM; MICROBIOLOGY; PATHOGENICITY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

ADAPTIVE IMMUNITY; ANIMALS; BIOMARKERS, TUMOR; COLORECTAL NEOPLASMS; FUSOBACTERIUM INFECTIONS; FUSOBACTERIUM NUCLEATUM; GASTROINTESTINAL MICROBIOME; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNITY, INNATE; LYMPHOCYTE ACTIVATION; LYMPHOCYTES, TUMOR-INFILTRATING; MICROSATELLITE INSTABILITY; T-LYMPHOCYTE SUBSETS; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84954441185     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v22.i2.557     Document Type: Review

References (96)

1. Schwabe RF, Jobin C. The microbiome and cancer. Nat Rev Cancer 2013; 13: 800-812 [PMID: 24132111 DOI: 10.1038/nrc3610]
2. Dickson RP, Martinez FJ, Huffnagle GB. The role of the microbiome in exacerbations of chronic lung diseases. Lancet 2014; 384: 691-702 [PMID: 25152271 DOI: 10.1016/S0140-6736(14)61136-3]
3. Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: perspectives on the past, present, and future. Lancet 2014; 383: 1068-1083 [PMID: 24315620 DOI: 10.1016/S0140-6736(13)62154-6]
4. Ogino S, Galon J, Fuchs CS, Dranoff G. Cancer immunology-analysis of host and tumor factors for personalized medicine. Nat Rev Clin Oncol 2011; 8: 711-719 [PMID: 21826083 DOI: 10.1038/nrclinonc.2011.122]
5. Tjalsma H, Boleij A, Marchesi JR, Dutilh BE. A bacterial driver-passenger model for colorectal cancer: beyond the usual suspects. Nat Rev Microbiol 2012; 10: 575-582 [PMID: 22728587 DOI: 10.1038/nrmicro2819]
6. Signat B, Roques C, Poulet P, Duffaut D. Fusobacterium nucleatum in periodontal health and disease. Curr Issues Mol Biol 2011; 13: 25-36 [PMID: 21220789]
7. Michaud DS, Izard J, Wilhelm-Benartzi CS, You DH, Grote VA, Tjønneland A, Dahm CC, Overvad K, Jenab M, Fedirko V, Boutron-Ruault MC, Clavel-Chapelon F, Racine A, Kaaks R, Boeing H, Foerster J, Trichopoulou A, Lagiou P, Trichopoulos D, Sacerdote C, Sieri S, Palli D, Tumino R, Panico S, Siersema PD, Peeters PH, Lund E, Barricarte A, Huerta JM, Molina-Montes E, Dorronsoro M, Quirós JR, Duell EJ, Ye W, Sund M, Lindkvist B, Johansen D, Khaw KT, Wareham N, Travis RC, Vineis P, Bueno-de-Mesquita HB, Riboli E. Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut 2013; 62: 1764-1770 [PMID: 22990306 DOI: 10.1136/gutjnl-2012-303006]
8. Michaud DS. Role of bacterial infections in pancreatic cancer. Carcinogenesis 2013; 34: 2193-2197 [PMID: 23843038 DOI: 10.1093/carcin/bgt249]
9. Ohkusa T, Okayasu I, Ogihara T, Morita K, Ogawa M, Sato N. Induction of experimental ulcerative colitis by Fusobacterium varium isolated from colonic mucosa of patients with ulcerative colitis. Gut 2003; 52: 79-83 [PMID: 12477765]
10. Minami M, Ando T, Okamoto A, Sasaki N, Ohkura T, Torii K, Hasegawa T, Ohta M, Goto H. Seroprevalence of Fusobacterium varium in ulcerative colitis patients in Japan. FEMS Immunol Med Microbiol 2009; 56: 67-72 [PMID: 19484811]
11. Strauss J, Kaplan GG, Beck PL, Rioux K, Panaccione R, Devinney R, Lynch T, Allen-Vercoe E. Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis 2011; 17: 1971-1978 [PMID: 21830275 DOI: 10.1002/ibd.21606]
12. Shahani L, Khardori N. Fusobacterium necrophorum-beyond Lemierres syndrome. BMJ Case Rep 2011; 2011: [PMID: 22674593 DOI: 10.1136/bcr.07.2011.4527]
13. Brook I, Frazier EH. Microbiological analysis of pancreatic abscess. Clin Infect Dis 1996; 22: 384-385 [PMID: 8838210]
14. Yoneda M, Kato S, Mawatari H, Kirikoshi H, Imajo K, Fujita K, Endo H, Takahashi H, Inamori M, Kobayashi N, Kubota K, Saito S, Tohnai I, Watanuki K, Wada K, Maeda S, Nakajima A. Liver abscess caused by periodontal bacterial infection with Fusobacterium necrophorum. Hepatol Res 2011; 41: 194-196 [PMID: 21269389 DOI: 10.1111/j.1872-034X.2010.00748.x]
15. Athavale NV, Leitch DG, Cowling P. Liver abscesses due to Fusobacterium spp that mimick malignant metastatic liver disease. Eur J Clin Microbiol Infect Dis 2002; 21: 884-886 [PMID: 12525925 DOI: 10.1007/s10096-002-0844-8]
16. Kostic AD, Gevers D, Pedamallu CS, Michaud M, Duke F, Earl AM, Ojesina AI, Jung J, Bass AJ, Tabernero J, Baselga J, Liu C, Shivdasani RA, Ogino S, Birren BW, Huttenhower C, Garrett WS, Meyerson M. Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res 2012; 22: 292-298 [PMID: 22009990 DOI: 10.1101/gr.126573.111]
17. Castellarin M, Warren RL, Freeman JD, Dreolini L, Krzywinski M, Strauss J, Barnes R, Watson P, Allen-Vercoe E, Moore RA, Holt RA. Fusobacterium nucleatum infection is prevalent in human colorectal carcinoma. Genome Res 2012; 22: 299-306 [PMID: 22009989 DOI: 10.1101/gr.126516.111]
18. Tahara T, Yamamoto E, Suzuki H, Maruyama R, Chung W, Garriga J, Jelinek J, Yamano HO, Sugai T, An B, Shureiqi I, Toyota M, Kondo Y, Estécio MR, Issa JP. Fusobacterium in colonic fora and molecular features of colorectal carcinoma. Cancer Res 2014; 74: 1311-1318 [PMID: 24385213 DOI: 10.1158/0008-5472. CAN-13-1865]
19. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570 [PMID: 21436444 DOI: 10.1126/science.1203486]
20. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, Burke MM, Caldwell A, Kronenberg SA, Agunwamba BU, Zhang X, Lowy I, Inzunza HD, Feely W, Horak CE, Hong Q, Korman AJ, Wigginton JM, Gupta A, Sznol M. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-133 [PMID: 23724867 DOI: 10.1056/NEJMoa1302369]
21. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, Chagorova T, de la Serna J, Dilhuydy MS, Illmer T, Opat S, Owen CJ, Samoylova O, Kreuzer KA, Stilgenbauer S, Döhner H, Langerak AW, Ritgen M, Kneba M, Asikanius E, Humphrey K, Wenger M, Hallek M. Obinutuzumab plus chlorambucil in patients with CLL and coexisting conditions. N Engl J Med 2014; 370: 1101-1110 [PMID: 24401022 DOI: 10.1056/NEJMoa1313984]
22. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, Walsh LA, Postow MA, Wong P, Ho TS, Hollmann TJ, Bruggeman C, Kannan K, Li Y, Elipenahli C, Liu C, Harbison CT, Wang L, Ribas A, Wolchok JD, Chan TA. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189-2199 [PMID: 25409260 DOI: 10.1056/NEJMoa1406498]
23. Herbst RS, Soria JC, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, Kohrt HE, Horn L, Lawrence DP, Rost S, Leabman M, Xiao Y, Mokatrin A, Koeppen H, Hegde PS, Mellman I, Chen DS, Hodi FS. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 2014; 515: 563-567 [PMID: 25428504 DOI: 10.1038/nature14011]
24. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, Shen X, Boyd Z, Hegde PS, Chen DS, Vogelzang NJ. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 2014; 515: 558-562 [PMID: 25428503 DOI: 10.1038/nature13904]
25. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature 2014; 515: 568-571 [PMID: 25428505 DOI: 10.1038/nature13954]
26. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Galon J. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 2005; 353: 2654-2666 [PMID: 16371631 DOI: 10.1056/NEJMoa051424]
27. Salama P, Phillips M, Grieu F, Morris M, Zeps N, Joseph D, Platell C, Iacopetta B. Tumor-infiltrating FOXP3+ T regulatory cells show strong prognostic significance in colorectal cancer. J Clin Oncol 2009; 27: 186-192 [PMID: 19064967 DOI: 10.1200/JCO.2008.18.7229]
28. Nosho K, Baba Y, Tanaka N, Shima K, Hayashi M, Meyerhardt JA, Giovannucci E, Dranoff G, Fuchs CS, Ogino S. Tumour-infltrating T-cell subsets, molecular changes in colorectal cancer, and prognosis: cohort study and literature review. J Pathol 2010; 222: 350-366 [PMID: 20927778 DOI: 10.1002/path.2774]
29. Llosa NJ, Cruise M, Tam A, Wicks EC, Hechenbleikner EM, Taube JM, Blosser RL, Fan H, Wang H, Luber BS, Zhang M, Papadopoulos N, Kinzler KW, Vogelstein B, Sears CL, Anders RA, Pardoll DM, Housseau F. The vigorous immune microenvironment of microsatellite instable colon cancer is balanced by multiple counter-inhibitory checkpoints. Cancer Discov 2015; 5: 43-51 [PMID: 25358689 DOI: 10.1158/2159-8290.CD-14-0863]
30. Shenker BJ, Listgarten MA, Taichman NS. Suppression of human lymphocyte responses by oral spirochetes: a monocyte-dependent phenomenon. J Immunol 1984; 132: 2039-2045 [PMID: 6699406]
31. Jewett A, Hume WR, Le H, Huynh TN, Han YW, Cheng G, Shi W. Induction of apoptotic cell death in peripheral blood mononuclear and polymorphonuclear cells by an oral bacterium, Fusobacterium nucleatum. Infect Immun 2000; 68: 1893-1898 [PMID: 10722579]
32. Kinder Haake S, Lindemann RA. Fusobacterium nucleatum T18 aggregates human mononuclear cells and inhibits their PHA-stimulated proliferation. J Periodontol 1997; 68: 39-44 [PMID: 9029450 DOI: 10.1902/jop.1997.68.1.39]
33. Shenker BJ, Datar S. Fusobacterium nucleatum inhibits human T-cell activation by arresting cells in the mid-G1 phase of the cell cycle. Infect Immun 1995; 63: 4830-4836 [PMID: 7591143]
34. Shenker BJ, Matt WC. Suppression of human lymphocyte responsiveness by forskolin: reversal by 12-O-tetradecanoyl phorbol 13-acetate, diacylglycerol and ionomycin. Immuno-pharmacology 1987; 13: 73-86 [PMID: 3032853]
35. Huynh T, Kapur RV, Kaplan CW, Cacalano N, Kinder Haake S, Shi W, Sieling P, Jewett A. The role of aggregation in Fusobacterium nucleatum-induced immune cell death. J Endod 2011; 37: 1531-1535 [PMID: 22000457 DOI: 10.1016/j.joen.2011.06.034]
36. Mima K, Sukawa Y, Nishihara R, Qian ZR, Yamauchi M, Inamura K, Kim SA, Masuda A, Nowak JA, Nosho K, Kostic AD, Giannakis M, Watanabe H, Bullman S, Milner DA, Harris CC, Giovannucci E, Garraway LA, Freeman GJ, Dranoff G, Chan AT, Garrett WS, Huttenhower C, Fuchs CS, Ogino S. Fusobacterium nucleatum and T Cells in Colorectal Carcinoma. JAMA Oncol 2015; 1: 653-661 [PMID: 26181352 DOI: 10.1001/jamaoncol.2015.1377]
37. Flanagan L, Schmid J, Ebert M, Soucek P, Kunicka T, Liska V, Bruha J, Neary P, Dezeeuw N, Tommasino M, Jenab M, Prehn JH, Hughes DJ. Fusobacterium nucleatum associates with stages of colorectal neoplasia development, colorectal cancer and disease outcome. Eur J Clin Microbiol Infect Dis 2014; 33: 1381-1390 [PMID: 24599709 DOI: 10.1007/s10096-014-2081-3]
38. Kostic AD, Chun E, Robertson L, Glickman JN, Gallini CA, Michaud M, Clancy TE, Chung DC, Lochhead P, Hold GL, El-Omar EM, Brenner D, Fuchs CS, Meyerson M, Garrett WS. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe 2013; 14: 207-215 [PMID: 23954159 DOI: 10.1016/j.chom.2013.07.007]
39. Schetter AJ, Heegaard NH, Harris CC. Infammation and cancer: interweaving microRNA, free radical, cytokine and p53 pathways. Carcinogenesis 2010; 31: 37-49 [PMID: 19955394 DOI: 10.1093/carcin/bgp272]
40. Ogino S, Nosho K, Irahara N, Meyerhardt JA, Baba Y, Shima K, Glickman JN, Ferrone CR, Mino-Kenudson M, Tanaka N, Dranoff G, Giovannucci EL, Fuchs CS. Lymphocytic reaction to colorectal cancer is associated with longer survival, independent of lymph node count, microsatellite instability, and CpG island methylator phenotype. Clin Cancer Res 2009; 15: 6412-6420 [PMID: 19825961 DOI: 10.1158/1078-0432.CCR-09-1438]
41. Schwitalle Y, Kloor M, Eiermann S, Linnebacher M, Kienle P, Knaebel HP, Tariverdian M, Benner A, von Knebel Doeberitz M. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008; 134: 988-997 [PMID: 18395080 DOI: 10.1053/j.gastro.2008.01.015]
42. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006; 6: 295-307 [PMID: 16557261 DOI: 10.1038/nri1806]
43. Speetjens FM, Kuppen PJ, Morreau H, van der Burg SH. Immune response against frameshift-induced neopeptides in HNPCC patients and healthy HNPCC mutation carriers. Gastroenterology 2008; 135: 711-712; author reply 712-713 [PMID: 18619460 DOI: 10.1053/j.gastro.2008.04.040]
44. Curiel TJ. Tregs and rethinking cancer immunotherapy. J Clin Invest 2007; 117: 1167-1174 [PMID: 17476346 DOI: 10.1172/JCI31202]
45. Disis ML, Bernhard H, Jaffee EM. Use of tumour-responsive T cells as cancer treatment. Lancet 2009; 373: 673-683 [PMID: 19231634 DOI: 10.1016/S0140-6736(09)60404-9]
46. Alexander J, Watanabe T, Wu TT, Rashid A, Li S, Hamilton SR. Histopathological identifcation of colon cancer with microsatellite instability. Am J Pathol 2001; 158: 527-535 [PMID: 11159189 DOI: 10.1016/S0002-9440(10)63994-6]
47. Shia J, Ellis NA, Paty PB, Nash GM, Qin J, Offt K, Zhang XM, Markowitz AJ, Nafa K, Guillem JG, Wong WD, Gerald WL, Klimstra DS. Value of histopathology in predicting microsatellite instability in hereditary nonpolyposis colorectal cancer and sporadic colorectal cancer. Am J Surg Pathol 2003; 27: 1407-1417 [PMID: 14576473]
48. Jenkins MA, Hayashi S, O'Shea AM, Burgart LJ, Smyrk TC, Shimizu D, Waring PM, Ruszkiewicz AR, Pollett AF, Redston M, Barker MA, Baron JA, Casey GR, Dowty JG, Giles GG, Limburg P, Newcomb P, Young JP, Walsh MD, Thibodeau SN, Lindor NM, Lemarchand L, Gallinger S, Haile RW, Potter JD, Hopper JL, Jass JR. Pathology features in Bethesda guidelines predict colorectal cancer microsatellite instability: a population-based study. Gastroenterology 2007; 133: 48-56 [PMID: 17631130 DOI: 10.1053/j.gastro.2007.04.044]
49. Tougeron D, Fauquembergue E, Rouquette A, Le Pessot F, Sesboüé R, Laurent M, Berthet P, Mauillon J, Di Fiore F, Sabourin JC, Michel P, Tosi M, Frébourg T, Latouche JB. Tumor-infltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. Mod Pathol 2009; 22: 1186-1195 [PMID: 19503063 DOI: 10.1038/modpathol.2009.80]
50. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-618 [PMID: 15659508 DOI: 10.1200/JCO.2005.01.086]
51. Sinicrope FA, Rego RL, Ansell SM, Knutson KL, Foster NR, Sargent DJ. Intraepithelial effector (CD3+)/regulatory (FoxP3+) T-cell ratio predicts a clinical outcome of human colon carcinoma. Gastroenterology 2009; 137: 1270-1279 [PMID: 19577568 DOI: 10.1053/j.gastro.2009.06.053]
52. Gabrilovich DI, Ostrand-Rosenberg S, Bronte V. Coordinated regulation of myeloid cells by tumours. Nat Rev Immunol 2012; 12: 253-268 [PMID: 22437938 DOI: 10.1038/nri3175]
53. Gabrilovich DI, Bronte V, Chen SH, Colombo MP, Ochoa A, Ostrand-Rosenberg S, Schreiber H. The terminology issue for myeloid-derived suppressor cells. Cancer Res 2007; 67: 425; author reply 426 [PMID: 17210725 DOI: 10.1158/0008-5472. CAN-06-3037]
54. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 2005; 65: 3437-3446 [PMID: 15833879 DOI: 10.1158/0008-5472. CAN-04-4262]
55. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12: 298-306 [PMID: 22419253 DOI: 10.1038/nrc3245]
56. Dong J, Zhao YP, Zhou L, Zhang TP, Chen G. Bcl-2 upregulation induced by miR-21 via a direct interaction is associated with apoptosis and chemoresistance in MIA PaCa-2 pancreatic cancer cells. Arch Med Res 2011; 42: 8-14 [PMID: 21376256 DOI: 10.1016/j.arcmed.2011.01.006]
57. Frampton AE, Giovannetti E, Jamieson NB, Krell J, Gall TM, Stebbing J, Jiao LR, Castellano L. A microRNA meta-signature for pancreatic ductal adenocarcinoma. Expert Rev Mol Diagn 2014; 14: 267-271 [PMID: 24575833 DOI: 10.1586/14737159.2014.893 192]
58. Ma MZ, Kong X, Weng MZ, Cheng K, Gong W, Quan ZW, Peng CH. Candidate microRNA biomarkers of pancreatic ductal adenocarcinoma: meta-analysis, experimental validation and clinical signifcance. J Exp Clin Cancer Res 2013; 32: 71 [PMID: 24289824 DOI: 10.1186/1756-9966-32-71]
59. Mace TA, Collins AL, Wojcik SE, Croce CM, Lesinski GB, Bloomston M. Hypoxia induces the overexpression of microRNA-21 in pancreatic cancer cells. J Surg Res 2013; 184: 855-860 [PMID: 23726431 DOI: 10.1016/j.jss.2013.04.061]
60. Nagao Y, Hisaoka M, Matsuyama A, Kanemitsu S, Hamada T, Fukuyama T, Nakano R, Uchiyama A, Kawamoto M, Yamaguchi K, Hashimoto H. Association of microRNA-21 expression with its targets, PDCD4 and TIMP3, in pancreatic ductal adenocarcinoma. Mod Pathol 2012; 25: 112-121 [PMID: 21983937 DOI: 10.1038/modpathol.2011.142]
61. Wang P, Zhuang L, Zhang J, Fan J, Luo J, Chen H, Wang K, Liu L, Chen Z, Meng Z. The serum miR-21 level serves as a predictor for the chemosensitivity of advanced pancreatic cancer, and miR-21 expression confers chemoresistance by targeting FasL. Mol Oncol 2013; 7: 334-345 [PMID: 23177026 DOI: 10.1016/j.molonc.2012.10.011]
62. Farrell JJ, Toste P, Wu N, Li L, Wong J, Malkhassian D, Tran LM, Wu X, Li X, Dawson D, Wu H, Donahue TR. Endoscopically acquired pancreatic cyst fuid microRNA 21 and 221 are associated with invasive cancer. Am J Gastroenterol 2013; 108: 1352-1359 [PMID: 23752880 DOI: 10.1038/ajg.2013.167]
63. Nosho K, Igarashi H, Ito M, Mitsuhashi K, Kurihara H, Kanno S, Yoshii S, Mikami M, Takahashi H, Kusumi T, Hosokawa M, Sukawa Y, Adachi Y, Hasegawa T, Okita K, Hirata K, Maruyama R, Suzuki H, Imai K, Yamamoto H, Shinomura Y. Clinicopathological and molecular characteristics of serrated lesions in Japanese elderly patients. Digestion 2015; 91: 57-63 [PMID: 25632919 DOI: 10.1159/000368820]
64. Igarashi H, Kurihara H, Mitsuhashi K, Ito M, Okuda H, Kanno S, Naito T, Yoshii S, Takahashi H, Kusumi T, Hasegawa T, Sukawa Y, Adachi Y, Okita K, Hirata K, Imamura Y, Baba Y, Imai K, Suzuki H, Yamamoto H, Nosho K, Shinomura Y. Association of MicroRNA-31-5p with Clinical Efficacy of Anti-EGFR Therapy in Patients with Metastatic Colorectal Cancer. Ann Surg Oncol 2015; 22: 2640-2648 [PMID: 25472647 DOI: 10.1245/s10434-014-4264-7]
65. Aoki H, Nosho K, Igarashi H, Ito M, Mitsuhashi K, Naito T, Yamamoto E, Tanuma T, Nomura M, Maguchi H, Shinohara T, Suzuki H, Yamamoto H, Shinomura Y. MicroRNA-31 expression in colorectal serrated pathway progression. World J Gastroenterol 2014; 20: 12346-12349 [PMID: 25232271 DOI: 10.3748/wjg.v20. i34.12346]
66. Ito M, Mitsuhashi K, Igarashi H, Nosho K, Naito T, Yoshii S, Takahashi H, Fujita M, Sukawa Y, Yamamoto E, Takahashi T, Adachi Y, Nojima M, Sasaki Y, Tokino T, Baba Y, Maruyama R, Suzuki H, Imai K, Yamamoto H, Shinomura Y. MicroRNA-31 expression in relation to BRAF mutation, CpG island methylation and colorectal continuum in serrated lesions. Int J Cancer 2014; 135: 2507-2515 [PMID: 24752710 DOI: 10.1002/ijc.28920]
67. Nosho K, Igarashi H, Nojima M, Ito M, Maruyama R, Yoshii S, Naito T, Sukawa Y, Mikami M, Sumioka W, Yamamoto E, Kurokawa S, Adachi Y, Takahashi H, Okuda H, Kusumi T, Hosokawa M, Fujita M, Hasegawa T, Okita K, Hirata K, Suzuki H, Yamamoto H, Shinomura Y. Association of microRNA-31 with BRAF mutation, colorectal cancer survival and serrated pathway. Carcinogenesis 2014; 35: 776-783 [PMID: 24242331 DOI: 10.1093/carcin/bgt374]
68. Schwarzenbach H, Nishida N, Calin GA, Pantel K. Clinical relevance of circulating cell-free microRNAs in cancer. Nat Rev Clin Oncol 2014; 11: 145-156 [PMID: 24492836 DOI: 10.1038/nrclinonc.2014.5]
69. Li Z, Rana TM. Therapeutic targeting of microRNAs: current status and future challenges. Nat Rev Drug Discov 2014; 13: 622-638 [PMID: 25011539 DOI: 10.1038/nrd4359]
70. Mitsuhashi K, Yamamoto I, Kurihara H, Kanno S, Ito M, Igarashi H, Ishigami K, Sukawa Y, Tachibana M, Takahashi H, Tokino T, Maruyama R, Suzuki H, Imai K, Shinomura Y, Yamamoto H, Nosho K. Analysis of the molecular features of rectal carcinoid tumors to identify new biomarkers that predict biological malignancy. Oncotarget 2015; 6: 22114-22125 [PMID: 26090613]
71. Mitsuhashi K, Nosho K, Sukawa Y, Matsunaga Y, Ito M, Kurihara H, Kanno S, Igarashi H, Naito T, Adachi Y, Tachibana M, Tanuma T, Maguchi H, Shinohara T, Hasegawa T, Imamura M, Kimura Y, Hirata K, Maruyama R, Suzuki H, Imai K, Yamamoto H, Shinomura Y. Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget 2015; 6: 7209-7220 [PMID: 25797243]
72. Virtue A, Wang H, Yang XF. MicroRNAs and toll-like receptor/interleukin-1 receptor signaling. J Hematol Oncol 2012; 5: 66 [PMID: 23078795 DOI: 10.1186/1756-8722-5-66]
73. Honda T, Takahashi N, Miyauchi S, Yamazaki K. Porphyromonas gingivalis lipopolysaccharide induces miR-146a without altering the production of infammatory cytokines. Biochem Biophys Res Commun 2012; 420: 918-925 [PMID: 22480686 DOI: 10.1016/j.bbrc.2012.03.102]
74. Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH, Post S, Allgayer H. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-2136 [PMID: 17968323 DOI: 10.1038/sj.onc.1210856]
75. Iliopoulos D, Jaeger SA, Hirsch HA, Bulyk ML, Struhl K. STAT3 activation of miR-21 and miR-181b-1 via PTEN and CYLD are part of the epigenetic switch linking infammation to cancer. Mol Cell 2010; 39: 493-506 [PMID: 20797623 DOI: 10.1016/j.molcel.2010.07.023]
76. Pencheva N, Tavazoie SF. Control of metastatic progression by microRNA regulatory networks. Nat Cell Biol 2013; 15: 546-554 [PMID: 23728460 DOI: 10.1038/ncb2769]
77. Hansen TF, Kjær-Frifeldt S, Christensen RD, Morgenthaler S, Blondal T, Lindebjerg J, Sørensen FB, Jakobsen A. Redefining high-risk patients with stage II colon cancer by risk index and microRNA-21: results from a population-based cohort. Br J Cancer 2014; 111: 1285-1292 [PMID: 25051407 DOI: 10.1038/bjc.2014.409]
78. Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, Yuen ST, Chan TL, Kwong DL, Au GK, Liu CG, Calin GA, Croce CM, Harris CC. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA 2008; 299: 425-436 [PMID: 18230780 DOI: 10.1001/jama.299.4.425]
79. Sempere LF, Preis M, Yezefski T, Ouyang H, Suriawinata AA, Silahtaroglu A, Conejo-Garcia JR, Kauppinen S, Wells W, Korc M. Fluorescence-based codetection with protein markers reveals distinct cellular compartments for altered MicroRNA expression in solid tumors. Clin Cancer Res 2010; 16: 4246-4255 [PMID: 20682703 DOI: 10.1158/1078-0432.CCR-10-1152]
80. Sheedy FJ, Palsson-McDermott E, Hennessy EJ, Martin C, O' Leary JJ, Ruan Q, Johnson DS, Chen Y, O'Neill LA. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. Nat Immunol 2010; 11: 141-147 [PMID: 19946272 DOI: 10.1038/ni.1828]
81. Merline R, Moreth K, Beckmann J, Nastase MV, Zeng-Brouwers J, Tralhão JG, Lemarchand P, Pfeilschifter J, Schaefer RM, Iozzo RV, Schaefer L. Signaling by the matrix proteoglycan decorin controls inflammation and cancer through PDCD4 and MicroRNA-21. Sci Signal 2011; 4: ra75 [PMID: 22087031 DOI: 10.1126/scisignal.2001868]
82. Lu L, Byrnes K, Han C, Wang Y, Wu T. miR-21 targets 15-PGDH and promotes cholangiocarcinoma growth. Mol Cancer Res 2014; 12: 890-900 [PMID: 24699315 DOI: 10.1158/1541-7786. MCR-13-0419]
83. Lippitz BE. Cytokine patterns in patients with cancer: a systematic review. Lancet Oncol 2013; 14: e218-e228 [PMID: 23639322 DOI: 10.1016/S1470-2045(12)70582-X]
84. Wang D, Dubois RN. Eicosanoids and cancer. Nat Rev Cancer 2010; 10: 181-193 [PMID: 20168319 DOI: 10.1038/nrc2809]
85. O'Callaghan G, Ryan A, Neary P, O'Mahony C, Shanahan F, Houston A. Targeting the EP1 receptor reduces Fas ligand expression and increases the antitumor immune response in an in vivo model of colon cancer. Int J Cancer 2013; 133: 825-834 [PMID: 23390011 DOI: 10.1002/ijc.28076]
86. Mao Y, Poschke I, Wennerberg E, Pico de Coaña Y, Egyhazi Brage S, Schultz I, Hansson J, Masucci G, Lundqvist A, Kiessling R. Melanoma-educated CD14+ cells acquire a myeloid-derived suppressor cell phenotype through COX-2-dependent mechanisms. Cancer Res 2013; 73: 3877-3887 [PMID: 23633486 DOI: 10.1158/0008-5472.CAN-12-4115]
87. Naito T, Nosho K, Ito M, Igarashi H, Mitsuhashi K, Yoshii S, Aoki H, Nomura M, Sukawa Y, Yamamoto E, Adachi Y, Takahashi H, Hosokawa M, Fujita M, Takenouchi T, Maruyama R, Suzuki H, Baba Y, Imai K, Yamamoto H, Ogino S, Shinomura Y. IGF2 differentially methylated region hypomethylation in relation to pathological and molecular features of serrated lesions. World J Gastroenterol 2014; 20: 10050-10061 [PMID: 25110432 DOI: 10.3748/wjg.v20.i29.10050]
88. Baba Y, Nosho K, Shima K, Huttenhower C, Tanaka N, Hazra A, Giovannucci EL, Fuchs CS, Ogino S. Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfte pyrosequencing, is associated with poor prognosis. Gastroenterology 2010; 139: 1855-1864 [PMID: 20682317 DOI: 10.1053/j.gastro.2010.07.050]
89. Liao X, Lochhead P, Nishihara R, Morikawa T, Kuchiba A, Yamauchi M, Imamura Y, Qian ZR, Baba Y, Shima K, Sun R, Nosho K, Meyerhardt JA, Giovannucci E, Fuchs CS, Chan AT, Ogino S. Aspirin use, tumor PIK3CA mutation, and colorectal-cancer survival. N Engl J Med 2012; 367: 1596-1606 [PMID: 23094721 DOI: 10.1056/NEJMoa1207756]
90. Nosho K, Kure S, Irahara N, Shima K, Baba Y, Spiegelman D, Meyerhardt JA, Giovannucci EL, Fuchs CS, Ogino S. A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology 2009; 137: 1609-1620.e1-e3 [PMID: 19686742 DOI: 10.1053/j.gastro.2009.08.002]
91. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Meyerhardt JA, Loda M, Giovannucci EL, Fuchs CS. CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer. Gut 2009; 58: 90-96 [PMID: 18832519 DOI: 10.1136/gut.2008.155473]
92. Rooney MS, Shukla SA, Wu CJ, Getz G, Hacohen N. Molecular and genetic properties of tumors associated with local immune cytolytic activity. Cell 2015; 160: 48-61 [PMID: 25594174 DOI: 10.1016/j.cell.2014.12.033]
93. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-264 [PMID: 22437870 DOI: 10.1038/nrc3239]
94. Kaplan CW, Ma X, Paranjpe A, Jewett A, Lux R, Kinder-Haake S, Shi W. Fusobacterium nucleatum outer membrane proteins Fap2 and RadD induce cell death in human lymphocytes. Infect Immun 2010; 78: 4773-4778 [PMID: 20823215 DOI: 10.1128/IAI.00567-10]
95. Janssen HL, Reesink HW, Lawitz EJ, Zeuzem S, Rodriguez-Torres M, Patel K, van der Meer AJ, Patick AK, Chen A, Zhou Y, Persson R, King BD, Kauppinen S, Levin AA, Hodges MR. Treatment of HCV infection by targeting microRNA. N Engl J Med 2013; 368: 1685-1694 [PMID: 23534542 DOI: 10.1056/NEJMoa1209026]
96. Cheng CJ, Bahal R, Babar IA, Pincus Z, Barrera F, Liu C, Svoronos A, Braddock DT, Glazer PM, Engelman DM, Saltzman WM, Slack FJ. MicroRNA silencing for cancer therapy targeted to the tumour microenvironment. Nature 2015; 518: 107-110 [PMID: 25409146 DOI: 10.1038/nature13905]